| Description | Darunavir Ethanolate (UIC 94017) is an HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS. |
| In vivo | Darunavir对野生型和PI抗性HIV有效，口服生物利用度为37%。需与ritonavir联用，可将生物利用度提高至82%[3]。 |
| Target activity | HIV-1 protease:1 nM (Ki) |
| Synonyms | 地瑞那韦乙醇盐, UIC 94017, Darunavir Ethanolate, TMC114, 达芦那韦乙醇 |
| molecular weight | 593.74 |
| Molecular formula | C29H43N3O8S |
| CAS | 635728-49-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 93 mg/mL (156.6 mM) Ethanol: < 1 mg/mL (insoluble or slightly soluble) |
| References | 1. Fujimoto H, et al. Biol Pharm Bull, 2009, 32(9), 1588-1593. 2. Molina JM, et al. Expert Opin Pharmacother, 2007, 8(12), 1951-1964. 3. Bhalekar MR, et al. In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. Drug Deliv. 2016 Sep;23(7):2581-2586. |